[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![equilyse1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1829453676387106817.png) Equilyse [@equilyse1](/creator/twitter/equilyse1) on x XXX followers
Created: 2025-07-17 11:31:21 UTC

$JNJ: $JNJ Q2 earnings: A diversified model drives growth! Raised full-year sales guidance by $2B and EPS by $XXXX despite STELARA headwinds. Oncology sales soared 22.3%, fueled by DARZALEX and CARVYKTI—the latter exceeding $439M with 100%+ growth. Aiming to be #1 in oncology by 2030 with $50B+ in sales.

TREMFYA grew 30.1%, eyeing $10B+ peak sales with Crohn's & ulcerative colitis uptake. SPRAVATO jumped XX% in neuroscience. MedTech also shined, with XXX% growth driven by cardiovascular (up over 22%!) and electrophysiology. Shockwave acquisition is expected to be a $13B MedTech platform by year-end.

J&J plans to submit its OTTAVA robotic surgery system for FDA approval next year. Expects 4.5%-5% operational sales growth for the full year and anticipates a XXX basis points improvement in operating margin. Pipeline milestones include potential approvals for TAR-200 and subcutaneous RYBREVANT.

![](https://pbs.twimg.com/media/GwDmjgsXgAASezP.png)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945808538669912558/c:line.svg)

**Related Topics**
[jnj](/topic/jnj)
[$10b](/topic/$10b)
[$50b](/topic/$50b)
[$439m](/topic/$439m)
[eps](/topic/eps)
[$2b](/topic/$2b)
[$jnj](/topic/$jnj)
[johnson johnson](/topic/johnson-johnson)

[Post Link](https://x.com/equilyse1/status/1945808538669912558)